Behçet's disease pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 35: Line 35:
==Gross Pathology==
==Gross Pathology==
*On gross pathology [[Oral ulcer|oral ulcers]], [[Sex organ|genital]] [[Ulcer|ulcers]], [[uveitis]], and [[Skin lesion|skin lesions]] are characteristic findings of Behcet disease.
*On gross pathology [[Oral ulcer|oral ulcers]], [[Sex organ|genital]] [[Ulcer|ulcers]], [[uveitis]], and [[Skin lesion|skin lesions]] are characteristic findings of Behcet disease.
<figure-inline>[[File:Behcet's syndrome 11.jpeg|502x502px]]</figure-inline>
[[File:Behcet's syndrome 11.jpeg|thumb|left|369x369px|Oral ulcers [https://commons.wikimedia.org/wiki/File%3ABullae_and_Bleb.JPG Source:By Samuel Freire da Silva, M.D. in homage to The Master And Professor Delso Bringel Calheiros]]]
<br clear="left" />


==Microscopic Pathology==
==Microscopic Pathology==

Revision as of 02:01, 3 May 2018

Behçet's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Behçet's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Behçet's disease pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Behçet's disease pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Behçet's disease pathophysiology

CDC on Behçet's disease pathophysiology

Behçet's disease pathophysiology in the news

Blogs on Behçet's disease pathophysiology</smal

Directions to Hospitals Treating Behçet's disease

Risk calculators and risk factors for Behçet's disease pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hamid Qazi, MD, BSc [2], Mahda Alihashemi M.D. [3]


Overview

It is understood that behcet disease is the result of vasculitis. It involves all sizes of blood vessels ( small, medium, and large). Arteries and veins are both involved in Behcet disease. Major mechanisms in pathogenesis of behcet disease include environmental factors such as bacteria, viruses, and heat shock proteins (present in some bacteria and some of the bacterial HSPs share similaritis with human HSPs), streptococci sanguinis, streptococci pyogenes and mycobacterium tuberculosis produce HSPs that trigger anti HSP60 and anti HSP65 antibodies and then they target human HSPs and immune response such as uveitis in parenchymal neuro-behcet disease, CD4+ T cells activation, secretion of cytokines and inflammation. Genes involved in the pathogenesis of behcet disease include human leukocyte antigens, particularly HLA-B51.

Pathophysiology

Pathogenesis

Genetics

Gross Pathology

Oral ulcers Source:By Samuel Freire da Silva, M.D. in homage to The Master And Professor Delso Bringel Calheiros


Microscopic Pathology

References

  1. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P (December 2016). "Behçet's disease physiopathology: a contemporary review". Auto Immun Highlights. 7 (1): 4. doi:10.1007/s13317-016-0074-1. PMC 4751097. PMID 26868128.
  2. Direskeneli H (2013). "Innate and Adaptive Responses to Heat Shock Proteins in Behcet's Disease". Genet Res Int. 2013: 249157. doi:10.1155/2013/249157. PMC 3893747. PMID 24490075.
  3. Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M (June 1999). "Behçet's disease and antibody titers to various heat-shock protein 60s". Ocul. Immunol. Inflamm. 7 (2): 69–74. PMID 10420201.
  4. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A (October 2009). "HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies". Arthritis Rheum. 61 (10): 1287–96. doi:10.1002/art.24642. PMC 3867978. PMID 19790126.
  5. Akpolat T, Koç Y, Yeniay I, Akpek G, Güllü I, Kansu E, Kiraz S, Ersoy F, Batman F, Kansu T (November 1992). "Familial Behçet's disease". Eur J Med. 1 (7): 391–5. PMID 1341477.
  6. Fresko I, Soy M, Hamuryudan V, Yurdakul S, Yavuz S, Tümer Z, Yazici H (January 1998). "Genetic anticipation in Behçet's syndrome". Ann. Rheum. Dis. 57 (1): 45–8. PMC 1752455. PMID 9536823.
  7. Wei F, Zhang YU, Li W (June 2016). "A meta-analysis of the association between Behçet's disease and MICA-A6". Biomed Rep. 4 (6): 741–745. doi:10.3892/br.2016.644. PMC 4887777. PMID 27284416.
  8. Sakane T, Takeno M (September 2000). "Novel approaches to Behçet's disease". Expert Opin Investig Drugs. 9 (9): 1993–2005. doi:10.1517/13543784.9.9.1993. PMID 11060788.
  9. Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A (May 2005). "Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease". Rheumatology (Oxford). 44 (5): 614–7. doi:10.1093/rheumatology/keh561. PMID 15705632.
  10. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP (March 2003). "Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?". Arthritis Rheum. 48 (3): 807–13. doi:10.1002/art.10815. PMID 12632436.
  11. Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F, Salvi F, Malatesta R, La Corte R, Triolo G, Ferrante A, Filippini D, Paolazzi G, Sarzi-Puttini P, Nicoli D, Farnetti E, Chen Q, Pulsatelli L (September 2004). "Vascular endothelial growth factor gene polymorphisms in Behçet's disease". J. Rheumatol. 31 (9): 1785–9. PMID 15338501.
  12. Nakao K, Isashiki Y, Sonoda S, Uchino E, Shimonagano Y, Sakamoto T (February 2007). "Nitric oxide synthase and superoxide dismutase gene polymorphisms in Behçet disease". Arch. Ophthalmol. 125 (2): 246–51. doi:10.1001/archopht.125.2.246. PMID 17296902.
  13. Tursen U, Tamer L, Api H, Yildirim H, Baz K, Ikizoglu G, Atik U (February 2007). "Cytochrome P450 polymorphisms in patients with Behcet's disease". Int. J. Dermatol. 46 (2): 153–6. doi:10.1111/j.1365-4632.2007.02957.x. PMID 17269966.
  14. Sousa I, Shahram F, Francisco D, Davatchi F, Abdollahi BS, Ghaderibarmi F, Nadji A, Mojarad Shafiee N, Xavier JM, Oliveira SA (October 2015). "Brief report: association of CCR1, KLRC4, IL12A-AS1, STAT4, and ERAP1 With Behçet's disease in Iranians". Arthritis Rheumatol. 67 (10): 2742–8. doi:10.1002/art.39240. PMID 26097239.
  15. Yalçin B, Atakan N, Dogan S (December 2014). "Association of interleukin-23 receptor gene polymorphism with Behçet disease". Clin. Exp. Dermatol. 39 (8): 881–7. doi:10.1111/ced.12400. PMID 25156021.
  16. Livneh A, Aksentijevich I, Langevitz P, Torosyan Y, G-Shoham N, Shinar Y, Pras E, Zaks N, Padeh S, Kastner DL, Pras M (March 2001). "A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behçet's disease (FMF-BD)". Eur. J. Hum. Genet. 9 (3): 191–6. doi:10.1038/sj.ejhg.5200608. PMID 11313758.

Template:WH Template:WS